Latest Healthcare It News

Clarity Pharmaceuticals has secured a second FDA Fast Track Designation for its 64Cu-SAR-bisPSMA diagnostic agent, aiming to revolutionize prostate cancer imaging and speed regulatory approval.

AMCIL Limited posted a half-year profit of $3.6 million, down 12.6%, yet its portfolio outperformed the S&P/ASX 200 with an 8.7% return. The company declared a steady interim dividend amid cautious market conditions.

Amcor plc has taken a pivotal step in its proposed merger with Berry Global by filing the definitive joint proxy statement with the SEC, setting the stage for shareholder votes in February. Integration planning is well underway as both companies prepare to unite their packaging expertise.

Respiri Limited reports a standout December quarter marked by a 67% surge in patient program enrolments and robust revenue growth, bolstered by strategic acquisition synergies from Orb Health. The company is poised for further expansion in 2025 amid promising contract negotiations and evolving US healthcare reimbursement policies.

4DMedical has signed a landmark commercial agreement with Qscan Radiology Clinics, marking its first Australian contract to integrate both Pulmonary Function and Pulmonary Structure imaging products.

Amcor plc and Berry Global Group, Inc. have entered into a definitive all-stock merger agreement, positioning the combined entity as a global leader in consumer and healthcare packaging with expected annual synergies of $650 million.

Amcor plc and Berry Global Group have filed their definitive joint proxy statement with the SEC, marking a key milestone in their planned all-stock merger. Shareholder meetings are scheduled for February 25, 2025, as the companies aim to create a global packaging powerhouse.

SomnoMed Limited reported a solid cash flow performance for Q4 2024, with operating activities generating a net inflow of $1.525 million and ending the quarter with $18.5 million in cash reserves.

SomnoMed reports a robust 19.8% revenue increase in Q2 FY25 and updates its full-year guidance, reflecting strong demand and operational improvements amid ongoing production enhancements.

Pacific Smiles Group reports robust patient fee growth of over 9% year-on-year and reaffirms FY25 guidance, while announcing a CFO change as Genesis Capital solidifies its majority stake.

InhalerX Limited reported a negative cash flow for the December quarter despite securing a substantial $38.5 million funding facility aimed at advancing its clinical trials. The company has yet to draw on this facility, maintaining a cautious cash position as it progresses its drug development programs.

InhaleRx has locked in a $38.5 million funding deal with Clendon Biotech Capital, enabling expanded Phase 2 trials for its inhaled breakthrough cancer pain and panic disorder treatments. The company also filed a key international patent, positioning itself for a faster path to FDA approval.